{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:07:01Z","timestamp":1793200021253,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473937"],"award-info":[{"award-number":["82473937"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hepatobiliary & Pancreatic Diseases International"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hbpd.2025.12.010","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:49:43Z","timestamp":1765471783000},"page":"125-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody-drug conjugates specifically regulate tumor microenvironment: A promising strategy for pancreatic cancer treatment"],"prefix":"10.1016","volume":"25","author":[{"given":"Jia-Le","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao-Ming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao-Jin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang-Ping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hbpd.2025.12.010_bib0001","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(14)61396-9","article-title":"40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study","volume":"385","author":"Quaresma","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0002","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0003","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jnci\/djz093","article-title":"Immunotherapy for colorectal cancer: a review of current and novel therapeutic approaches","volume":"111","author":"Franke","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0004","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.32163","article-title":"Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer","volume":"125","author":"Piawah","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106404","article-title":"Impact of postal correspondence letters on participation in cancer screening: a rapid review","volume":"145","author":"Yakubu","year":"2021","journal-title":"Prev Med"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0006","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-019-0804-8","article-title":"Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment","volume":"12","author":"Yang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196040","article-title":"Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment","volume":"13","author":"Sceneay","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107514","article-title":"Curcumin suppresses crosstalk between colon cancer stem cells and stromal fibroblasts in the tumor microenvironment: potential role of EMT","volume":"9","author":"Buhrmann","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0009","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0010","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0012","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1158\/2159-8290.CD-19-0958","article-title":"Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0013","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41416-019-0479-5","article-title":"Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features","volume":"121","author":"Karamitopoulou","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0014","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.691185","article-title":"Targeting the stroma in the management of pancreatic cancer","volume":"11","author":"Edwards","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1287459","article-title":"Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target","volume":"15","author":"Hartupee","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0017","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0018","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.3390\/molecules26195847","article-title":"An insight into FDA approved antibody-drug conjugates for cancer therapy","volume":"26","author":"Tong","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0019","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the 'high-hanging fruit","volume":"17","author":"Carter","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.hoc.2013.10.009","article-title":"Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug","volume":"28","author":"Okeley","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0021","first-page":"165","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0022","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-20-3119","article-title":"FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer","volume":"27","author":"Wahby","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0023","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0024","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","article-title":"The immune revolution: a case for priming, not checkpoint","volume":"33","author":"Vonderheide","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0026","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/srep35848","article-title":"Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma","volume":"6","author":"Bailey","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1721727X221092900","article-title":"Advance of T regulatory cells in tumor microenvironment remodeling and immunotherapy in pancreatic cancer","volume":"20","author":"Gao","year":"2022","journal-title":"Eur J Inflamm"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0029","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13287-016-0388-y","article-title":"Chemotaxis-driven disease-site targeting of therapeutic adult stem cells in dystrophic epidermolysis bullosa","volume":"7","author":"Alexeev","year":"2016","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0030","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: positioning cells for host defense and immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0031","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/gutjnl-2016-312078","article-title":"Myeloid cells are required for PD-1\/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer","volume":"66","author":"Zhang","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0032","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","article-title":"Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity","volume":"63","author":"Stromnes","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0033","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0034","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0035","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00262-011-1178-0","article-title":"Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth","volume":"61","author":"Porembka","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0036","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2017.12.012","article-title":"Emerging trends in the immunotherapy of pancreatic cancer","volume":"417","author":"Banerjee","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0037","first-page":"62","article-title":"Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer","volume":"4","author":"Gulhati","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0038","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3389\/fimmu.2014.00491","article-title":"Macrophage cytokines: involvement in immunity and infectious diseases","volume":"5","author":"Arango Duque","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103315","article-title":"Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression","volume":"66","author":"Chen","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0040","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s13402-021-00594-0","article-title":"Role of TGF-\u03b2 in pancreatic ductal adenocarcinoma progression and PD-L1 expression","volume":"44","author":"Hussain","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0041","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/0008-5472.CAN-17-3841","article-title":"Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN\/PI3K\u03b3 to promote pancreatic cancer metastasis","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0042","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12964-018-0262-x","article-title":"Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction","volume":"16","author":"Feng","year":"2018","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0043","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1158\/0008-5472.CAN-11-2194","article-title":"Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization","volume":"72","author":"Tugues","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0044","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12964-021-00789-w","article-title":"Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review","volume":"19","author":"Li","year":"2021","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105317","article-title":"Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer","volume":"25","author":"Sarhan","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0046","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4049\/jimmunol.1301342","article-title":"Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4","volume":"192","author":"Volont\u00e9","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0047","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41467-018-04313-6","article-title":"STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion","volume":"9","author":"Hsu","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0048","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.canlet.2019.06.005","article-title":"Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-\u03b21\/smad2\/3 axis in pancreatic cancer","volume":"459","author":"Zhang","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000253","article-title":"Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity","volume":"8","author":"Xi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0050","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nrc2013","article-title":"Cancer as an evolutionary and ecological process","volume":"6","author":"Merlo","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0051","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.celrep.2017.06.062","article-title":"Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer","volume":"20","author":"Jang","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0052","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1067\/msy.2002.119937","article-title":"Paucity of dendritic cells in pancreatic cancer","volume":"131","author":"Dallal","year":"2002","journal-title":"Surgery"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013441","article-title":"Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor","volume":"5","author":"Tjomsland","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0054","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nrc3545","article-title":"MSP-RON signalling in cancer: pathogenesis and therapeutic potential","volume":"13","author":"Yao","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0055","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1158\/0008-5472.CAN-06-4128","article-title":"The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression","volume":"67","author":"Thomas","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0056","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/path.2245","article-title":"Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells","volume":"213","author":"Wang","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0057","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41419-022-04799-5","article-title":"HGF\/c-met pathway facilitates the perineural invasion of pancreatic cancer by activating the mTOR\/NGF axis","volume":"13","author":"Qin","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0058","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","article-title":"Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma","volume":"29","author":"Peng","year":"2019","journal-title":"Cell Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0059","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0060","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s43018-023-00526-x","article-title":"Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy","volume":"4","author":"B\u00e4rthel","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0061","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.ymthe.2022.04.013","article-title":"A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors","volume":"30","author":"Wu","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0062","doi-asserted-by":"crossref","first-page":"9344","DOI":"10.1039\/D0CC03396K","article-title":"Clustered nanobody-drug conjugates for targeted cancer therapy","volume":"56","author":"Wu","year":"2020","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0063","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1158\/0008-5472.CAN-13-2990","article-title":"Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids","volume":"74","author":"Perrino","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0064","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/ijc.30569","article-title":"Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix","volume":"140","author":"G\u00e9bleux","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006274","article-title":"An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer","volume":"11","author":"Wittwer","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0066","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0067","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1158\/1535-7163.MCT-14-0599","article-title":"A chemically defined trifunctional antibody-cytokine-drug conjugate with potent antitumor activity","volume":"13","author":"List","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0068","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","article-title":"Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies","volume":"77","author":"Rios-Doria","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0069","doi-asserted-by":"crossref","first-page":"315ra188","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"M\u00fcller","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","article-title":"A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer","volume":"7","author":"D\u2019Amico","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0071","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/0008-5472.CAN-20-0434","article-title":"Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade","volume":"81","author":"Boshuizen","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0072","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1565859","article-title":"Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells","volume":"8","author":"Bauzon","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0073","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0074","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-17-0019","article-title":"Tumor-associated macrophages can contribute to antitumor activity through fc\u03b3r-mediated processing of antibody-drug cnjugates","volume":"16","author":"Li","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0075","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0076","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-20-0014","article-title":"First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer","volume":"20","author":"Pegram","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0077","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0078","first-page":"A244","article-title":"Phase 1\/2 study of novel HER2-targeting, TLR7\/8 immune-stimulating antibody conjugate(ISAC)BDC-1001 with or without immune checkpoint inhibitor in patients withadvanced HER2-expressing solid tumors","volume":"8","author":"Sharma","year":"2020","journal-title":"J Immunotherapy Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0079","doi-asserted-by":"crossref","first-page":"15716","DOI":"10.1021\/acs.jmedchem.1c00961","article-title":"Immune modulating antibody-drug conjugate (IM-ADC) for cancer immunotherapy","volume":"64","author":"He","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0080","doi-asserted-by":"crossref","first-page":"50735","DOI":"10.18632\/oncotarget.9383","article-title":"Targeting tumor-associated macrophages to combat pancreatic cancer","volume":"7","author":"Cui","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0081","doi-asserted-by":"crossref","first-page":"119","DOI":"10.21037\/atm-20-1076","article-title":"Immune profiling and immunotherapeutic targets in pancreatic cancer","volume":"9","author":"Lenzo","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0082","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","article-title":"Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions","volume":"12","author":"Hiraoka","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0083","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00262-014-1565-4","article-title":"The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity","volume":"63","author":"Martin","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0084","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/13543784.2011.573477","article-title":"The development of pyrrolobenzodiazepines as antitumour agents","volume":"20","author":"Hartley","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","article-title":"A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy","volume":"29","author":"Li","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0086","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","article-title":"Resistance to antibody-drug conjugates","volume":"78","author":"Garc\u00eda-Alonso","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0087","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1158\/1078-0432.CCR-09-0586","article-title":"CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates","volume":"15","author":"Govindan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0088","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1053\/j.gastro.2012.06.037","article-title":"T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice","volume":"143","author":"Chmielewski","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0089","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0090","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40425-019-0525-0","article-title":"Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate zt\/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy","volume":"7","author":"Yao","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0091","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1021\/acs.molpharmaceut.8b00298","article-title":"Preclinical efficacy of anti-RON antibody drug-conjugate zt\/g4-MMAE for targeted therapy of pancreatic cancer overexpressing RON receptor tyrosine kinase","volume":"15","author":"Yao","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0092","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0093","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0094","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1073\/pnas.1323934111","article-title":"Intratumor heterogeneity alters most effective drugs in designed combinations","volume":"111","author":"Zhao","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0095","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032882","article-title":"The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes","volume":"102","author":"Kayikcioglu","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100762","article-title":"Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer","volume":"8","author":"Kubota","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0097","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jconrel.2021.05.004","article-title":"Nanobodies as efficient drug-carriers: progress and trends in chemotherapy","volume":"334","author":"Panikar","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188360","article-title":"RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: pathogenic mechanism in malignancy and pharmaceutical target for therapy","volume":"1873","author":"Yao","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0099","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920920069","article-title":"Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials","volume":"12","author":"Yao","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0100","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.3748\/wjg.v27.i20.2507","article-title":"RON in hepatobiliary and pancreatic cancers: pathogenesis and potential therapeutic targets","volume":"27","author":"Chen","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0101","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1158\/1078-0432.CCR-20-3210","article-title":"A MET targeting antibody-drug conjugate overcomes gemcitabine resistance in pancreatic cancer","volume":"27","author":"Cazes","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0102","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canlet.2007.08.007","article-title":"Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets","volume":"257","author":"Lu","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0103","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7555\/JBR.27.20130038","article-title":"Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction","volume":"27","author":"Wang","year":"2013","journal-title":"J Biomed Res"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.hbpd.2025.12.010_bib0105","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/1538-7445.AM2020-5203","article-title":"MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3, exhibits immunomodulatory activity and enhanced antitumor activity in combination with checkpoint inhibitors","volume":"80","author":"Scribner","year":"2020","journal-title":"Cancer Res"}],"container-title":["Hepatobiliary & Pancreatic Diseases International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387225002243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387225002243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:42:32Z","timestamp":1778816552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499387225002243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1499387225002243"],"URL":"https:\/\/doi.org\/10.1016\/j.hbpd.2025.12.010","relation":{},"ISSN":["1499-3872"],"issn-type":[{"value":"1499-3872","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-drug conjugates specifically regulate tumor microenvironment: A promising strategy for pancreatic cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Hepatobiliary & Pancreatic Diseases International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hbpd.2025.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}